Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
(2018) In British Journal of Haematology 182(4). p.583-586
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/03ca04e0-8db7-4914-9f9e-6bef9df5642c
- author
- organization
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Antibody-drug conjugate, B-cell non-Hodgkin lymphoma, CD22+, Inotuzumab ozogamicin, Rituximab
- in
- British Journal of Haematology
- volume
- 182
- issue
- 4
- pages
- 583 - 586
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85021842393
- pmid:28677896
- ISSN
- 0007-1048
- DOI
- 10.1111/bjh.14820
- language
- English
- LU publication?
- yes
- id
- 03ca04e0-8db7-4914-9f9e-6bef9df5642c
- date added to LUP
- 2017-08-18 13:35:20
- date last changed
- 2024-09-16 06:39:07
@misc{03ca04e0-8db7-4914-9f9e-6bef9df5642c, author = {{Dang, Nam H. and Ogura, Michinori and Castaigne, Sylvie and Fayad, Luis E. and Jerkeman, Mats and Radford, John and Pezzutto, Antonio and Bondarenko, Igor N. and Stewart, Douglas A. and Shnaidman, Michael and Sullivan, Sharon and Vandendries, Erik and Tobinai, Kensei and Ramchandren, Radhakrishnan and Hamlin, Paul A. and Giné, Eva and Ando, Kiyoshi}}, issn = {{0007-1048}}, keywords = {{Antibody-drug conjugate; B-cell non-Hodgkin lymphoma; CD22+; Inotuzumab ozogamicin; Rituximab}}, language = {{eng}}, number = {{4}}, pages = {{583--586}}, publisher = {{Wiley-Blackwell}}, series = {{British Journal of Haematology}}, title = {{Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma}}, url = {{http://dx.doi.org/10.1111/bjh.14820}}, doi = {{10.1111/bjh.14820}}, volume = {{182}}, year = {{2018}}, }